We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Portuguese spin out: Des Solutio

30 Oct 2018 07:00

RNS Number : 5786F
Frontier IP Group plc
30 October 2018
 

30 October 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Second Portuguese spin out Des Solutio to develop green chemistry for beauty, pharmaceutical and food industries

 

Frontier IP, a specialist in commercialising university intellectual property, today announces it is taking a 25 per cent. stake in Des Solutio (the "Company"), a company developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal care and other products.

 

The Company has been established to develop and commercialise the research of Associate Professor Ana Rita Duarte and Dr Alexandre Paiva, of Portugal's NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA").

 

Their research has already attracted interest from several major industrial groups, including a world-leading cosmetics company and a major pharmaceutical company. In return for its stake, Frontier IP will provide Des Solutio with a broad range of commercialisation services, including contract negotiation and identifying and working with potential industry partners to validate and scale up the technology.

 

Des Solutio is developing new methods to use Natural Deep Eutectic Solvents ("NADES") in cosmetics, nutraceuticals and other applications, to replace toxic organic solvents, such as ethanol, employed currently. Solvents are commonly used in a wide range of industries to extract active ingredients from natural matrices, such as olive oil, mint or seaweed to flavour and scent their products, and enhance the shelf-life and stability of the bioactives.

 

NADES offer many benefits over existing solvents. Found in a vast range of plants, and so compliant with a green chemistry philosophy, they are entirely derived from natural compounds such as organic acids, amino acids and sugars.

 

As there are a vast range of NADES already identified, they can be matched to specific active ingredients to extract only what is needed. There is no need to recover an active ingredient from a NADES, unlike conventional solvents, some of which are too toxic for use on skin or in foods.

 

Other advantages of the technology include improved solubility, permeability and bioavailability of the active compounds, better biodegradability than many organic solvents and greener production processes.

 

The incorporation of Des Solutio is a further sign of Frontier IP's growing momentum in Portugal. It is the Group's second spin out from FCT NOVA following NTPE, a company developing novel technology to print electronic circuits, sensors and semiconductors on to paper. The Group recently entered into a strategic partnership with the UK government's Department for International Trade in Portugal.

 

Des Solutio co-founder, Associate Professor Ana Rita Duarte said:  "We're delighted to be working with Frontier IP on developing and bringing this ground-breaking science into the commercial world. NADES have huge potential for making a host of everyday products greener and saferfor people to use."

 

Frontier IP chief executive Neil Crabb said: "We're very excited about the possibilities for Des Solutio. The technology being developed by Professor Ana Rita Duarte and Dr Alexandre Paiva has already attracted interest from major multinationals. Its incorporation as our second Portuguese spin out is further sign of our growing strength in the country."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABLBDGBGDBGIC
Date   Source Headline
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update
28th Apr 20217:00 amRNSExscientia Series D funding led by SoftBank

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.